1-5 of 5
Mollie Moran
Close
Sort by
Journal Articles

Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL

Kerry A Rogers, Eric McLaughlin, Lai Wei, Seema A Bhat, Arianna Crouse, Michael R. Grever, Dan Jones, Adam S Kittai, Gerard Lozanski, Mollie Moran, Mark Reid, Ellen J Sass, Swetha Suresh, John C. Byrd, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 1899.
https://doi.org/10.1182/blood-2023-180294
Published: 2023
Journal Articles

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Thomas S. Lin, James T. Dalton, Di Wu, Mitch A. Phelps, Beth Fischer, Mollie Moran, Kristie A. Blum, Brad Rovin, Michelle Brooker-McEldowney, Sarah Broering, Larry J. Schaaf, Amy J. Johnson, David M. Lucas, Nyla A. Heerema, Gerard Lozanski, Donn C. Young, Jose-Ramon Suarez, A. Dimitrios Colevas, Michael R. Grever
Journal: Blood
Blood (2006) 109 (2): 399–404.
https://doi.org/10.1182/blood-2006-05-020735
Published: 2006
Journal Articles

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia

Clinical Trials & Observations
John C. Byrd, Guido Marcucci, Mark R. Parthun, Jim J. Xiao, Rebecca B. Klisovic, Mollie Moran, Thomas S. Lin, Shujun Liu, Amy R. Sklenar, Melanie E. Davis, David M. Lucas, Beth Fischer, Roshini Shank, Sooraj L. Tejaswi, Philip Binkley, John Wright, Kenneth K. Chan, Michael R. Grever
Journal: Blood
Blood (2005) 105 (3): 959–967.
https://doi.org/10.1182/blood-2004-05-1693
Published: 2005
Journal Articles

Decitabine-Induced Differentiation Syndrome in a Patient with Acute Myeloid Leukemia: A Case Report.

William Blum, M.D., Kristie A. Blum, M.D., Cheryl Kefauver, R.N., Mollie Moran, C.R.N.P., Kenneth Chan, Ph.D., John C. Byrd, M.D., Spero Cataland, M.D., Michael R. Grever, M.D., Guido Marcucci, M.D.
Journal: Blood
Blood (2004) 104 (11): 4528.
https://doi.org/10.1182/blood.V104.11.4528.4528
Published: 2004
Journal Articles

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

Clinical Trials & Observations
Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Lisa Smith, Jennifer Harbison, Jennifer Webb, Mollie Moran, Margaret Lucas, Thomas Lin, Marcy L. Hackbarth, John H. Proffitt, David Lucas, Michael R. Grever, John C. Byrd
Journal: Blood
Blood (2004) 103 (9): 3278–3281.
https://doi.org/10.1182/blood-2003-10-3729
Published: 2004